- KR₩255bn
- KR₩276bn
- KR₩4bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.93 | ||
| Price to Tang. Book | 0.94 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 59.09 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.73% | ||
| Return on Equity | -14.12% | ||
| Operating Margin | -887.1% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | 11,303.05 | 18,543.49 | 36,828.45 | 16,139.03 | 4,426.63 | 10,000 | 21,000 | -19.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Genexine Inc is a Korea-based company mainly engaged in the research and development of bio pharmaceuticals. The Company operates its business through two segments. The New Drug Development segment engages in human growth hormone, neutropenia treatment, anemia treatment, anticancer immunotherapy, hyFc platform, and other technology transfers. In addition, this segment sells the technical property rights of follicle-stimulating hormone. It also engages in cell line construction and sample production, project development, animal testing, human growth hormone development, and government agency research. The Medical Consumables segment produces and sells medical consumables such as medicine bags.
Directors
- Yeong Cheol Sung CEO (59)
- Byeong Gwon Lee VPR (52)
- Gi Seon Ohn MDR (54)
- Bok Hwan Jeon MDR (49)
- Yeong Su Choi MDR (48)
- Se Hwan Yang OTH (43)
- Chang Hun Lee OTH (54)
- Wu Yik Jang DRC (56)
- Myeong Ho Jung DRC (48)
- Mi Jeong Ahn NID (59)
- Yeong Tae Yoon NID (60)
- Last Annual
- December 31st, 2023
- Last Interim
- June 30th, 2024
- Incorporated
- June 8th, 1999
- Public Since
- September 15th, 2009
- No. of Shareholders
- 92,137
- No. of Employees
- 80
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Korea Exchange - KOSDAQ- Shares in Issue
- 41,449,778
- Address
- Korea Bio Park, SEONGNAM, 13488
- Web
- http://genexine.com/
- Phone
- +82 260982600
- Auditors
- KPMG Samjong Accounting Corp
Upcoming Events for 095700
Q4 2024 Genexine Inc Earnings Release
Genexine Inc Annual Shareholders Meeting
Similar to 095700
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
AptaBio Therapeutics
Korea Exchange - KOSDAQ
FAQ
What is the Genexine share price?
As of Today at 20:48 UTC, shares in Genexine are trading at KR₩6,160. This share price information is delayed by 15 minutes.
How has the Genexine share price performed this year?
Shares in Genexine last closed at KR₩6,160 and the price had moved by -30.32% over the past 365 days. In terms of relative price strength the Genexine share price has underperformed the FTSE Developed Asia Pacific Index by -40.5% over the past year.
What are the analyst and broker recommendations for Genexine?
The overall consensus recommendation for Genexine is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Genexine dividend yield?
Genexine does not currently pay a dividend.
Does Genexine pay a dividend?
Genexine does not currently pay a dividend.
When does Genexine next pay dividends?
Genexine does not currently pay a dividend.
How do I buy Genexine shares?
To buy shares in Genexine you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Genexine?
As of the previous close price of KR₩6,160, shares in Genexine had a market capitalisation of KR₩255bn.
Where are Genexine shares listed?
Here are the trading details for Genexine:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 095700
What kind of share is Genexine?
Based on an overall assessment of its quality, value and momentum Genexine is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Genexine share price forecast for 2024?
The analyst consensus target price for shares in Genexine is KR₩95,000. That is 1442.21% above the last closing price of KR₩6,160.
Analysts covering Genexine currently have a consensus Earnings Per Share (EPS) forecast of -KR₩1,066 for the next financial year.
Find out moreWhat is the trend in the Genexine share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Genexine. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -29.55%.
As of the last closing price of KR₩6,160, shares in Genexine were trading -20.7% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Genexine PE Ratio?
The Genexine PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩6,160.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Genexine?
Genexine's management team is headed by:
- Yeong Cheol Sung - CEO
- Byeong Gwon Lee - VPR
- Gi Seon Ohn - MDR
- Bok Hwan Jeon - MDR
- Yeong Su Choi - MDR
- Se Hwan Yang - OTH
- Chang Hun Lee - OTH
- Wu Yik Jang - DRC
- Myeong Ho Jung - DRC
- Mi Jeong Ahn - NID
- Yeong Tae Yoon - NID